The DOI matches its Crossref record.
Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis
Open accessAbstract
OBJECTIVE: To evaluate the efficacy of adalimumab in juvenile idiopathic arthritis (JIA)-associated uveitis. METHODS: Retrospective observational study of 20 patients with JIA and chronic uveitis on adalimumab treatment. The ocular inflammation and improvement was assessed according to the Standardization of Uveitis Nomenclature criteria. RESULTS: At the initiation of adalimumab, the mean age of patients was 13.4 yrs and the mean duration of uveitis 8.7 yrs. Seventeen (85%) patients had polyarticular JIA and 19 (95%) had previously been on anti-TNF treatment. The mean duration of adalimumab therapy was 18.7 months. Of the 20 patients, 7 (35%) showed improved activity, 1 (5%) worsening activity and in 12 (60%) no change was observed in the activity of uveitis. Those with improved activity were younger and had shorter disease duration. The mean number of flares/yr decreased from 1.9 to 1.4 during adalimumab treatment. Serious adverse events or side-effects were not observed. Seven patients discontinued adalimumab during the follow-up: six because of inefficacy and one because of inactive uveitis. CONCLUSION: Adalimumab is a potential treatment option in JIA-associated uveitis, even in patients non-responsive to previous other anti-TNF therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Nguyen, Q. D., Merrill, P. T., Jaffe, G. J., Dick, A. D., Kurup, S. K., Sheppard, J., Schlaen, A., Pavesio, C., Cimino, L., Van Calster, J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31339-3 · Cited by 536
Levy-Clarke, G., Jabs, D. A., Read, R. W., Rosenbaum, J. T., Vitale, A., & Van Gelder, R. N. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.09.048 · Cited by 483
Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis
Ramanan, A. V., Dick, A. D., Jones, A. P., McKay, A., Williamson, P. R., Compeyrot-Lacassagne, S., Hardwick, B., Hickey, H., Hughes, D., Woo, P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614160 · Cited by 437
Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis
Dick, A. D., Rosenbaum, J. T., Al-Dhibi, H. A., Belfort, R., Brézin, A. P., Chee, S. P., Davis, J. L., Ramanan, A. V., Sonoda, K.-H., Carreño, E., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.11.017 · Cited by 285
Self-citation
Metadata
- Authors
- Tynjala, P., Kotaniemi, K., Lindahl, P., Latva, K., Aalto, K., Honkanen, V., & Lahdenne, P.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-11-28
- Volume
- 47
- Issue
- 3
- Pages
- 339-344
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2026718163
- Cited by
- 185
- References
- 0
- FWCI
- 6.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. https://app.cochat.ai/papers/10.1093/rheumatology/kem356
- The paper
- Tynjala, P., Kotaniemi, K., Lindahl, P., Latva, K., Aalto, K., Honkanen, V., & Lahdenne, P. (2007). Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology. https://doi.org/10.1093/rheumatology/kem356
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.